June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Articles|August 22, 2012
Insight Software ranked on Inc. 500|5000 list
Author(s)Ophthalmology Times Staff Reports
Insight Software, creators of My Vision Express, has been ranked by Inc. magazine as one of the nation's fastest-growing private companies.
Advertisement
New York-Insight Software, creators of
My Vision Express is a practice management and electronic health record software certified by a testing and certification body authorized by the Office of the National Coordinator for Health Information Technology and designed specifically for eye-care professionals.
Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at
For more information about Insight Software, visit
For more articles in this issue of Ophthalmology Times eReport,
You May Also Be Interested In...
Advertisement
Related to this article
Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
ARPA-H funds OCULAB to build tear-duct sensors that track biomarkers in real time and microdose drugs, transforming dry-eye and systemic care.
A balanced mix of AI-generated and smartphone-captured images eliminated the domain-specific failures seen with single-source training
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
4
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
5